Breaking News Instant updates and real-time market news.

MTUAY

MTU Aero Engines

$120.76 /

+6.34 (+5.54%)

15:33
02/17/22
02/17
15:33
02/17/22
15:33

MTU Aero Engines price target raised to EUR 178 from EUR 176 at Morgan Stanley

Morgan Stanley analyst Andrew Humphrey raised the firm's price target on MTU Aero Engines to EUR 178 from EUR 176 and keeps an Underweight rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
Oppenheimer retail analysts to hold an analyst/industry conference call » 23:56
12/06/22
12/06
23:56
12/06/22
23:56

Retail Analysts, along…

Retail Analysts, along with Jack Kleinhenz, Chief Economist of the National Retail Federation, participate in an Analyst/Industry conference call to be held on December 14.

Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 23:54
12/06/22
12/06
23:54
12/06/22
23:54
KURA

Kura Oncology

$15.40 /

-0.45 (-2.84%)

, SNDX

Syndax

$24.21 /

-1.255 (-4.93%)

, APTO

Aptose Biosciences

/

+

, CRIS

Curis

/

+

, KRON

Kronos Bio

$1.66 /

-0.09 (-5.14%)

, SLS

Sellas Life Sciences

$2.42 /

-0.1 (-3.97%)

, GBT

Bought by PFE

$68.49 /

+ (+0.00%)

, VINC

Vincerx Pharma

/

+

, ALXO

ALX Oncology

$10.62 /

-1.06 (-9.08%)

, GILD

Gilead

$87.97 /

-0.05 (-0.06%)

, TRIL

Trillium Therapeutics

$18.45 /

+ (+0.00%)

Biotech Analyst Watsek…

Biotech Analyst Watsek and Biopharma & Biotech Analysts Chen and Kim provide a review of ASH 2022 of emerging therapies for Hematologic Malignancies: AML, MDS, MM and CLL on an Analyst/Industry conference call to be held on December 14 at 11 am. Webcast Link

ShowHide Related Items >><<
VINC Vincerx Pharma
/

+

SNDX Syndax
$24.21 /

-1.255 (-4.93%)

SLS Sellas Life Sciences
$2.42 /

-0.1 (-3.97%)

KURA Kura Oncology
$15.40 /

-0.45 (-2.84%)

KRON Kronos Bio
$1.66 /

-0.09 (-5.14%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

GBT Bought by PFE
$68.49 /

+ (+0.00%)

CRIS Curis
/

+

APTO Aptose Biosciences
/

+

ALXO ALX Oncology
$10.62 /

-1.06 (-9.08%)

KURA Kura Oncology
$15.40 /

-0.45 (-2.84%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
SNDX Syndax
$24.21 /

-1.255 (-4.93%)

09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
07/28/22 B. Riley
Syndax resumed with a Buy at B. Riley
04/11/22 H.C. Wainwright
Syndax initiated with a Buy at H.C. Wainwright
02/14/22 Goldman Sachs
Syndax initiated with a Buy at Goldman Sachs
APTO Aptose Biosciences
/

+

08/03/22 Cantor Fitzgerald
Aptose Biosciences price target lowered to $6 from $10 at Cantor Fitzgerald
04/28/22 Cantor Fitzgerald
Aptose Biosciences assumed with an Overweight at Cantor Fitzgerald
12/20/21 Piper Sandler
Aptose Biosciences price target lowered to $3 from $7 at Piper Sandler
12/20/21 H.C. Wainwright
Aptose price target lowered to $12 from $14 at H.C. Wainwright
CRIS Curis
/

+

04/11/22 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Curis, says new partial hold not a surprise
04/05/22 Cantor Fitzgerald
Curis price target lowered to $4 from $12 at Cantor Fitzgerald
04/05/22 B. Riley
Curis price target lowered to $10 from $22 at B. Riley
04/04/22 Raymond James
Raymond James downgrades Curis after emavusertib put on partial clinical hold
KRON Kronos Bio
$1.66 /

-0.09 (-5.14%)

11/18/22 H.C. Wainwright
Kronos Bio price target lowered to $10 from $36 at H.C. Wainwright
11/09/22 Piper Sandler
Kronos Bio price target lowered to $7 from $13 at Piper Sandler
09/14/22 Berenberg
Kronos Bio initiated with a Buy at Berenberg
05/23/22 Piper Sandler
Kronos Bio price target lowered to $13 from $30 at Piper Sandler
SLS Sellas Life Sciences
$2.42 /

-0.1 (-3.97%)

11/15/22 Alliance Global Partners
Sellas Life Sciences price target lowered to $8 from $14 at Alliance Global
06/28/22 Cantor Fitzgerald
Sellas Life Sciences price target lowered to $6 from $10 at Cantor Fitzgerald
04/07/22 Alliance Global Partners
Sellas Life Sciences price target lowered to $14 from $16.50 at Alliance Global Partners
GBT Bought by PFE
$68.49 /

+ (+0.00%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 RBC Capital
Global Blood downgraded to Sector Perform from Outperform at RBC Capital
08/08/22 Cowen
Global Blood Therapeutics downgraded to Market Perform from Outperform at Cowen
VINC Vincerx Pharma
/

+

11/16/22 Chardan
Vincerx Pharma price target lowered to $3 from $4 at Chardan
06/08/22 Cantor Fitzgerald
Vincerx Pharma price target lowered to $8 from $22 at Cantor Fitzgerald
06/07/22 B. Riley
Vincerx Pharma price target lowered to $6 from $12 at B. Riley
06/07/22 Chardan
Vincerx Pharma price target lowered to $4 from $11 at Chardan
ALXO ALX Oncology
$10.62 /

-1.06 (-9.08%)

11/09/22 Cantor Fitzgerald
ALX Oncology price target lowered to $22 from $32 at Cantor Fitzgerald
11/09/22 H.C. Wainwright
ALX Oncology price target lowered to $65 from $80 at H.C. Wainwright
08/09/22 Cantor Fitzgerald
ALX Oncology price target lowered to $32 from $60 at Cantor Fitzgerald
08/09/22 Credit Suisse
ALX Oncology price target lowered to $38 from $43 at Credit Suisse
GILD Gilead
$87.97 /

-0.05 (-0.06%)

12/05/22 RBC Capital
Gilead discontinuation 'curious,' but shouldn't derail cancer momentum, says RBC
12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
TRIL Trillium Therapeutics
$18.45 /

+ (+0.00%)

VINC Vincerx Pharma
/

+

SNDX Syndax
$24.21 /

-1.255 (-4.93%)

KURA Kura Oncology
$15.40 /

-0.45 (-2.84%)

KRON Kronos Bio
$1.66 /

-0.09 (-5.14%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

GBT Bought by PFE
$68.49 /

+ (+0.00%)

CRIS Curis
/

+

APTO Aptose Biosciences
/

+

ALXO ALX Oncology
$10.62 /

-1.06 (-9.08%)

  • 07
    Dec
  • 01
    Apr
  • 16
    Dec
GBT Bought by PFE
$68.49 /

+ (+0.00%)

SNDX Syndax
$24.21 /

-1.255 (-4.93%)

KURA Kura Oncology
$15.40 /

-0.45 (-2.84%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

GBT Bought by PFE
$68.49 /

+ (+0.00%)

SLS Sellas Life Sciences
$2.42 /

-0.1 (-3.97%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

GBT Bought by PFE
$68.49 /

+ (+0.00%)

CRIS Curis
/

+

Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 23:50
12/06/22
12/06
23:50
12/06/22
23:50
NVS

Novartis

$90.76 /

-0.23 (-0.25%)

, GILD

Gilead

$87.97 /

-0.05 (-0.06%)

, BMY

Bristol-Myers

$79.91 /

-0.79 (-0.98%)

, JNJ

Johnson & Johnson

$176.04 /

-2.75 (-1.54%)

, GRCL

Gracell

$2.55 /

-0.43 (-14.43%)

, PSTX

Poseida Therapeutics

$4.82 /

-0.27 (-5.30%)

, PGEN

Precigen

$1.58 /

-0.17 (-9.71%)

, MBIO

Mustang Bio

/

+

, ACLX

Arcellx

$19.01 /

-0.39 (-2.01%)

, ALLO

Allogene Therapeutics

$8.78 /

-0.575 (-6.15%)

, FATE

Fate Therapeutics

$19.18 /

-1.24 (-6.07%)

, HARP

Harpoon Therapeutics

/

+

Biopharma/Biotech…

Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies' treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.82 /

-0.27 (-5.30%)

PGEN Precigen
$1.58 /

-0.17 (-9.71%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.55 /

-0.43 (-14.43%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

FATE Fate Therapeutics
$19.18 /

-1.24 (-6.07%)

BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

ALLO Allogene Therapeutics
$8.78 /

-0.575 (-6.15%)

ACLX Arcellx
$19.01 /

-0.39 (-2.01%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
10/26/22 JPMorgan
Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
10/14/22 Barclays
Novartis price target lowered to CHF 75 from CHF 85 at Barclays
10/07/22 Deutsche Bank
Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
GILD Gilead
$87.97 /

-0.05 (-0.06%)

12/05/22 RBC Capital
Gilead discontinuation 'curious,' but shouldn't derail cancer momentum, says RBC
12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
GRCL Gracell
$2.55 /

-0.43 (-14.43%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
PSTX Poseida Therapeutics
$4.82 /

-0.27 (-5.30%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PGEN Precigen
$1.58 /

-0.17 (-9.71%)

11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
ACLX Arcellx
$19.01 /

-0.39 (-2.01%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$8.78 /

-0.575 (-6.15%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
FATE Fate Therapeutics
$19.18 /

-1.24 (-6.07%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
HARP Harpoon Therapeutics
/

+

11/15/22 Baird
Harpoon Therapeutics downgraded to Neutral from Outperform at Baird
08/29/22 Citi
Harpoon Therapeutics price target lowered to $6 from $7 at Citi
08/23/22 Truist
Harpoon Therapeutics price target lowered to $7 from $12 at Truist
08/15/22 H.C. Wainwright
Harpoon Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
PSTX Poseida Therapeutics
$4.82 /

-0.27 (-5.30%)

PGEN Precigen
$1.58 /

-0.17 (-9.71%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.55 /

-0.43 (-14.43%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

FATE Fate Therapeutics
$19.18 /

-1.24 (-6.07%)

BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

ALLO Allogene Therapeutics
$8.78 /

-0.575 (-6.15%)

ACLX Arcellx
$19.01 /

-0.39 (-2.01%)

  • 04
    Aug
  • 17
    Jun
  • 04
    Feb
NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

GRCL Gracell
$2.55 /

-0.43 (-14.43%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

FATE Fate Therapeutics
$19.18 /

-1.24 (-6.07%)

BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

ALLO Allogene Therapeutics
$8.78 /

-0.575 (-6.15%)

ACLX Arcellx
$19.01 /

-0.39 (-2.01%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

GILD Gilead
$87.97 /

-0.05 (-0.06%)

BMY Bristol-Myers
$79.91 /

-0.79 (-0.98%)

ACLX Arcellx
$19.01 /

-0.39 (-2.01%)

Conference/Events
BTIG energy transition analyst holds an analyst/industry conference call » 23:41
12/06/22
12/06
23:41
12/06/22
23:41

Energy Transition Analyst…

Energy Transition Analyst Lewis provides a Natural Gas and LNG update with Rystad Energy on an Analyst/Industry conference call to be held on December 13 at 1 pm.

Conference/Events
Cantor Fitzgerald pharma/biotech analysts hold a dinner » 23:18
12/06/22
12/06
23:18
12/06/22
23:18
APLS

Apellis

$46.92 /

-2.47 (-5.00%)

, ISEE

Iveric bio

$21.14 /

-0.745 (-3.40%)

, JNJ

Johnson & Johnson

$176.04 /

-2.75 (-1.54%)

, NVS

Novartis

$90.76 /

-0.23 (-0.25%)

, AKTX

Akari Therapeutics

/

+

, BLTE

Belite Bio

$32.70 /

-0.1 (-0.30%)

, LCTX

Lineage Cell Therapeutics

$1.40 /

-0.025 (-1.75%)

, OCGN

Ocugen

$1.40 /

-0.1 (-6.69%)

, REGN

Regeneron

$747.57 /

-8.1 (-1.07%)

, RHHBY

Roche

$40.27 /

-0.55 (-1.35%)

, EYPT

EyePoint

$3.11 /

-0.22 (-6.61%)

, OCUL

Ocular Therapeutix

$2.91 /

-0.1 (-3.33%)

, CLSD

Clearside Biomedical

$1.11 /

-0.02 (-1.77%)

, FDMT

4D Molecular

$21.83 /

-1.33 (-5.74%)

In conjunction with…

In conjunction with Cantor's Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference, Pharmaceuticals & Biotech Analysts Chen, Kim and Brayer, along with Drs. Clewner Hafler and Jewelewicz, focus on the Ophthalmology Industry for 2023 at an Ophthalmology Physician Dinner to be held in Miami on December 8 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

AKTX Akari Therapeutics
/

+

APLS Apellis
$46.92 /

-2.47 (-5.00%)

11/18/22 Cowen
Apellis should trade to $70 upon pegectacoplan approval, says Cowen
11/10/22 Jefferies
Apellis downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Iveric bio downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Apellis downgraded to Hold from Buy at Jefferies
ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

11/10/22 Jefferies
Iveric bio downgraded to Hold from Buy at Jefferies
10/17/22 B. Riley
Iveric bio upgraded to Neutral at B. Riley after competitor in GA 'disappoints'
JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
NVS Novartis
$90.76 /

-0.23 (-0.25%)

12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
10/26/22 JPMorgan
Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
10/14/22 Barclays
Novartis price target lowered to CHF 75 from CHF 85 at Barclays
10/07/22 Deutsche Bank
Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
AKTX Akari Therapeutics
/

+

12/05/22 H.C. Wainwright
Akari Therapeutics initiated with a Buy at H.C. Wainwright
11/01/22 Alliance Global Partners
Akari Therapeutics initiated with a Buy at Alliance Global Partners
BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

08/01/22 H.C. Wainwright
Belite Bio initiated with a Buy at H.C. Wainwright
07/01/22 Benchmark
Belite Bio initiated with a Buy at Benchmark
LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

11/01/22 Baird
Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
11/01/22 Baird
Lineage Cell Therapeutics initiated with an Outperform at Baird
06/14/22 B. Riley
B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
06/14/22 B. Riley
Lineage Cell Therapeutics initiated with a Buy at B. Riley
OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

08/23/22 Mizuho
Ocugen initiated with a Buy at Mizuho
08/15/22 H.C. Wainwright
Ocugen price target lowered to $6 from $7 at H.C. Wainwright
06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
REGN Regeneron
$747.57 /

-8.1 (-1.07%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

12/02/22 BofA
Hookipa Pharma downgraded to Underperform from Buy at BofA
11/29/22 Guggenheim
Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim
11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

11/08/22 H.C. Wainwright
Ocular Therapeutix price target lowered to $9 from $10 at H.C. Wainwright
11/08/22 Raymond James
Ocular Therapeutix price target lowered to $14 from $29 at Raymond James
09/29/22 Piper Sandler
Ocular Therapeutix data 'paint a compelling profile,' says Piper Sandler
09/27/22 Piper Sandler
Ocular Therapeutix hit/beat on Phase I study expectations, says Piper Sandler
CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

11/10/22 Needham
Clearside Biomedical upgraded to Buy from Hold at Needham
11/10/22 H.C. Wainwright
Clearside Biomedical price target raised to $6 from $5 at H.C. Wainwright
11/09/22 Stifel
Clearside Biomedical upgraded to Buy at Stifel after positive trial readout
11/09/22 Stifel
Clearside Biomedical upgraded to Buy from Hold at Stifel
FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

11/18/22 H.C. Wainwright
4D Molecular initiated with a Buy at H.C. Wainwright
11/15/22 Goldman Sachs
4D Molecular upgraded to Buy from Neutral at Goldman Sachs
11/14/22 BofA
4D Molecular price target raised to $25 from $15 at BofA
11/14/22 Evercore ISI
4D Molecular price target raised to $45 from $32 at Evercore ISI
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

AKTX Akari Therapeutics
/

+

  • 01
    Dec
  • 29
    Apr
  • 24
    Mar
  • 23
    Feb
REGN Regeneron
$747.57 /

-8.1 (-1.07%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

Conference/Events
Cantor Fitzgerald pharma/biotech analyst hold a luncheon » 23:15
12/06/22
12/06
23:15
12/06/22
23:15
APLS

Apellis

$46.92 /

-2.47 (-5.00%)

, ISEE

Iveric bio

$21.14 /

-0.745 (-3.40%)

, JNJ

Johnson & Johnson

$176.04 /

-2.75 (-1.54%)

, NVS

Novartis

$90.76 /

-0.23 (-0.25%)

, AKTX

Akari Therapeutics

/

+

, BLTE

Belite Bio

$32.70 /

-0.1 (-0.30%)

, LCTX

Lineage Cell Therapeutics

$1.40 /

-0.025 (-1.75%)

, OCGN

Ocugen

$1.40 /

-0.1 (-6.69%)

, REGN

Regeneron

$747.57 /

-8.1 (-1.07%)

, RHHBY

Roche

$40.27 /

-0.55 (-1.35%)

, EYPT

EyePoint

$3.11 /

-0.22 (-6.61%)

, OCUL

Ocular Therapeutix

$2.91 /

-0.1 (-3.33%)

, CLSD

Clearside Biomedical

$1.11 /

-0.02 (-1.77%)

, FDMT

4D Molecular

$21.83 /

-1.33 (-5.74%)

In conjunction with…

In conjunction with Cantor's Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference, Pharmaceuticals & Biotech Analysts Chen, Kim and Brayer, along with Drs. Ashraf, Chacon and Galimberti, discuss key new treatments in aesthetic dermatology at a luncheon meeting to be held in Miami on December 8 at 12:15 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

AKTX Akari Therapeutics
/

+

APLS Apellis
$46.92 /

-2.47 (-5.00%)

11/18/22 Cowen
Apellis should trade to $70 upon pegectacoplan approval, says Cowen
11/10/22 Jefferies
Apellis downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Iveric bio downgraded to Hold at Jefferies after doctor survey
11/10/22 Jefferies
Apellis downgraded to Hold from Buy at Jefferies
ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

11/10/22 Jefferies
Iveric bio downgraded to Hold from Buy at Jefferies
10/17/22 B. Riley
Iveric bio upgraded to Neutral at B. Riley after competitor in GA 'disappoints'
JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
NVS Novartis
$90.76 /

-0.23 (-0.25%)

12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
10/26/22 JPMorgan
Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
10/14/22 Barclays
Novartis price target lowered to CHF 75 from CHF 85 at Barclays
10/07/22 Deutsche Bank
Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
AKTX Akari Therapeutics
/

+

12/05/22 H.C. Wainwright
Akari Therapeutics initiated with a Buy at H.C. Wainwright
11/01/22 Alliance Global Partners
Akari Therapeutics initiated with a Buy at Alliance Global Partners
BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

08/01/22 H.C. Wainwright
Belite Bio initiated with a Buy at H.C. Wainwright
07/01/22 Benchmark
Belite Bio initiated with a Buy at Benchmark
LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

11/01/22 Baird
Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
11/01/22 Baird
Lineage Cell Therapeutics initiated with an Outperform at Baird
06/14/22 B. Riley
B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
06/14/22 B. Riley
Lineage Cell Therapeutics initiated with a Buy at B. Riley
OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

08/23/22 Mizuho
Ocugen initiated with a Buy at Mizuho
08/15/22 H.C. Wainwright
Ocugen price target lowered to $6 from $7 at H.C. Wainwright
06/15/22 Roth Capital
Ocugen resumed at Buy at Roth Capital on COVAXIN and OCU400 potential
06/15/22 Roth Capital
Ocugen resumed at Buy from Neutral at Roth Capital
REGN Regeneron
$747.57 /

-8.1 (-1.07%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

12/02/22 BofA
Hookipa Pharma downgraded to Underperform from Buy at BofA
11/29/22 Guggenheim
Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim
11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

11/08/22 H.C. Wainwright
Ocular Therapeutix price target lowered to $9 from $10 at H.C. Wainwright
11/08/22 Raymond James
Ocular Therapeutix price target lowered to $14 from $29 at Raymond James
09/29/22 Piper Sandler
Ocular Therapeutix data 'paint a compelling profile,' says Piper Sandler
09/27/22 Piper Sandler
Ocular Therapeutix hit/beat on Phase I study expectations, says Piper Sandler
CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

11/10/22 Needham
Clearside Biomedical upgraded to Buy from Hold at Needham
11/10/22 H.C. Wainwright
Clearside Biomedical price target raised to $6 from $5 at H.C. Wainwright
11/09/22 Stifel
Clearside Biomedical upgraded to Buy at Stifel after positive trial readout
11/09/22 Stifel
Clearside Biomedical upgraded to Buy from Hold at Stifel
FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

11/18/22 H.C. Wainwright
4D Molecular initiated with a Buy at H.C. Wainwright
11/15/22 Goldman Sachs
4D Molecular upgraded to Buy from Neutral at Goldman Sachs
11/14/22 BofA
4D Molecular price target raised to $25 from $15 at BofA
11/14/22 Evercore ISI
4D Molecular price target raised to $45 from $32 at Evercore ISI
RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

EYPT EyePoint
$3.11 /

-0.22 (-6.61%)

CLSD Clearside Biomedical
$1.11 /

-0.02 (-1.77%)

AKTX Akari Therapeutics
/

+

  • 01
    Dec
  • 29
    Apr
  • 24
    Mar
  • 23
    Feb
REGN Regeneron
$747.57 /

-8.1 (-1.07%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

RHHBY Roche
$40.27 /

-0.55 (-1.35%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCUL Ocular Therapeutix
$2.91 /

-0.1 (-3.33%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

LCTX Lineage Cell Therapeutics
$1.40 /

-0.025 (-1.75%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

FDMT 4D Molecular
$21.83 /

-1.33 (-5.74%)

BLTE Belite Bio
$32.70 /

-0.1 (-0.30%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

REGN Regeneron
$747.57 /

-8.1 (-1.07%)

OCGN Ocugen
$1.40 /

-0.1 (-6.69%)

NVS Novartis
$90.76 /

-0.23 (-0.25%)

JNJ Johnson & Johnson
$176.04 /

-2.75 (-1.54%)

ISEE Iveric bio
$21.14 /

-0.745 (-3.40%)

APLS Apellis
$46.92 /

-2.47 (-5.00%)

Conference/Events
Compass Point financial analysts hold analyst/industry conference call » 23:13
12/06/22
12/06
23:13
12/06/22
23:13

Financial Analysts…

Financial Analysts discuss private debt credit explanations on an Analyst/Industry conference call to be held on December 8.

Conference/Events
The Deputy Governor of the Bank of Canada delivers a speech » 23:00
12/06/22
12/06
23:00
12/06/22
23:00

Deputy Governor Kozicki…

Deputy Governor Kozicki of The Bank of Canada delivers the Economic Progress Report before the Institut de developpement urbain du Quebec on December 7 at 12:45 pm. Webcast Link

Downgrade
Achilles Therapeutics downgraded to Perform from Outperform at Oppenheimer » 21:45
12/06/22
12/06
21:45
12/06/22
21:45
ACHL

Achilles Therapeutics

$1.50 /

-0.215 (-12.57%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach downgraded Achilles Therapeutics to Perform from Outperform without a price target after the company presented new clinical data from the ongoing CHIRON and THETIS trials of its clonal neoantigen T-cell therapy. With no clear efficacy advantage for clonal neoantigen T-cells over conventional tumor-infiltrating lymphocytes, Achilles must make "significant optimizations before cNeTs could become commercially viable," Breidenbach tells investors in a research note. He moved to the sidelines pending "more convincing clinical proof-of-concept."

ShowHide Related Items >><<
ACHL Achilles Therapeutics
$1.50 /

-0.215 (-12.57%)

ACHL Achilles Therapeutics
$1.50 /

-0.215 (-12.57%)

12/06/22 Piper Sandler
Achilles Therapeutics price target lowered to $8 from $10 at Piper Sandler
12/06/22 Chardan
Achilles Therapeutics price target lowered to $17 from $20 at Chardan
05/27/22 Piper Sandler
Achilles Therapeutics price target lowered to $10 from $17 at Piper Sandler
05/10/22 Piper Sandler
Achilles Therapeutics price target lowered to $17 from $20 at Piper Sandler
ACHL Achilles Therapeutics
$1.50 /

-0.215 (-12.57%)

Downgrade
M&T Bank downgraded to Market Perform from Outperform at Keefe Bruyette » 21:07
12/06/22
12/06
21:07
12/06/22
21:07
MTB

M&T Bank

$160.43 /

-0.9 (-0.56%)

Keefe Bruyette analyst…

Keefe Bruyette analyst David Konrad downgraded M&T Bank to Market Perform from Outperform with a price target of $180, down from $215. Following last quarter's earning miss, M&T's recent guidance suggests lower than expected net interest margin coupled with lower than expected fees, Konrad tells investors in a research note. The analyst believes further outperformance of the shares may be challenging "at this stage of the rate cycle."

ShowHide Related Items >><<
MTB M&T Bank
$160.43 /

-0.9 (-0.56%)

MTB M&T Bank
$160.43 /

-0.9 (-0.56%)

12/05/22 Morgan Stanley
M&T Bank assumed with an Overweight at Morgan Stanley
10/21/22 Citi
M&T Bank price target lowered to $180 from $200 at Citi
10/20/22 Wedbush
M&T Bank price target lowered to $170 from $187 at Wedbush
10/20/22 Piper Sandler
M&T Bank price target lowered to $195 from $210 at Piper Sandler
MTB M&T Bank
$160.43 /

-0.9 (-0.56%)

MTB M&T Bank
$160.43 /

-0.9 (-0.56%)

MTB M&T Bank
$160.43 /

-0.9 (-0.56%)

Hot Stocks
Five Below director sells $9.1M, CEO sells $1.9M in common stock » 21:02
12/06/22
12/06
21:02
12/06/22
21:02
FIVE

Five Below

$180.62 /

-2.7 (-1.47%)

In a regulatory filing,…

In a regulatory filing, Five Below disclosed that its director Thomas Vellios sold 50K shares and CEO Joel Anderson sold 10K shares of common stock on December 2nd in respective transactions of $9.1M and $1.9M.

ShowHide Related Items >><<
FIVE Five Below
$180.62 /

-2.7 (-1.47%)

FIVE Five Below
$180.62 /

-2.7 (-1.47%)

12/02/22 Deutsche Bank
Five Below price target lowered to $201 from $205 at Deutsche Bank
12/01/22 Truist
Five Below price target raised to $196 from $161 at Truist
12/01/22 Craig-Hallum
Five Below price target raised to $200 from $178 at Craig-Hallum
12/01/22 Evercore ISI
Five Below price target raised to $170 from $155 at Evercore ISI
FIVE Five Below
$180.62 /

-2.7 (-1.47%)

FIVE Five Below
$180.62 /

-2.7 (-1.47%)

FIVE Five Below
$180.62 /

-2.7 (-1.47%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
12/06/22
12/06
20:25
12/06/22
20:25
BF.B

Brown-Forman

$73.70 /

-0.29 (-0.39%)

, BF.A

Brown-Forman

$73.23 /

-0.64 (-0.87%)

, CPB

Campbell Soup

$52.99 /

-0.325 (-0.61%)

, ASO

Academy Sports

$49.31 /

+1.015 (+2.10%)

, OLLI

Ollie's Bargain Outlet

$57.74 /

+0.41 (+0.72%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Brown-Forman (BF.B), consensus 55c... Campbell Soup (CPB), consensus 88c... Academy Sports and Outdoors (ASO), consensus $1.59... Ollie's Bargain Outlet (OLLI), consensus 41c.

ShowHide Related Items >><<
OLLI Ollie's Bargain Outlet
$57.74 /

+0.41 (+0.72%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

BF.B Brown-Forman
$73.70 /

-0.29 (-0.39%)

BF.A Brown-Forman
$73.23 /

-0.64 (-0.87%)

ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

BF.B Brown-Forman
$73.70 /

-0.29 (-0.39%)

10/10/22 Wedbush
Brown-Forman initiated with a Neutral at Wedbush
10/10/22 Wedbush
Brown-Forman initiated with a Neutral at Wedbush
09/28/22 Truist
Brown-Forman reinstated with a Buy at Truist
08/25/22 Barclays
Brown-Forman price target raised to $73 from $72 at Barclays
BF.A Brown-Forman
$73.23 /

-0.64 (-0.87%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

11/15/22 Exane BNP Paribas
Campbell Soup initiated with an Underperform at Exane BNP Paribas
09/13/22 UBS
Campbell Soup's top-line guidance may be hard to achieve, says UBS
09/02/22 Piper Sandler
Campbell Soup price target lowered to $46 from $47 at Piper Sandler
08/25/22 JPMorgan
Campbell Soup price target raised to $49 from $46 at JPMorgan
ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

11/28/22 Wedbush
Black Friday winners Include Best Buy, losers include Pets, says Wedbush
09/09/22 Loop Capital
Academy Sports initiated with a Buy at Loop Capital
09/08/22 UBS
Academy Sports price target raised to $60 from $55 at UBS
09/08/22 Evercore ISI
Academy Sports price target raised to $60 from $55 at Evercore ISI
OLLI Ollie's Bargain Outlet
$57.74 /

+0.41 (+0.72%)

10/24/22 Gordon Haskett
Ollie's Bargain Outlet initiated with a Buy at Gordon Haskett
09/16/22 JPMorgan
Ollie's Bargain Outlet price target raised to $54 from $40 at JPMorgan
09/02/22 Truist
Ollie's Bargain Outlet price target raised to $50 from $40 at Truist
08/30/22 Citi
Citi cautious into Ollie's results, opens 'negative catalyst watch'
OLLI Ollie's Bargain Outlet
$57.74 /

+0.41 (+0.72%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

BF.B Brown-Forman
$73.70 /

-0.29 (-0.39%)

ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

BF.B Brown-Forman
$73.70 /

-0.29 (-0.39%)

ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

OLLI Ollie's Bargain Outlet
$57.74 /

+0.41 (+0.72%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

CPB Campbell Soup
$52.99 /

-0.325 (-0.61%)

ASO Academy Sports
$49.31 /

+1.015 (+2.10%)

Hot Stocks
Cathie Wood's ARK Investment bought 330.4K shares of Verve Therapeutics today  20:19
12/06/22
12/06
20:19
12/06/22
20:19
VERV

Verve Therapeutics

$21.08 /

-0.32 (-1.50%)

 
ShowHide Related Items >><<
VERV Verve Therapeutics
$21.08 /

-0.32 (-1.50%)

VERV Verve Therapeutics
$21.08 /

-0.32 (-1.50%)

12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
08/24/22 Stifel
Verve Therapeutics upgraded to Buy at Stifel on upside from near-term catalysts
VERV Verve Therapeutics
$21.08 /

-0.32 (-1.50%)

  • 21
    Jul
VERV Verve Therapeutics
$21.08 /

-0.32 (-1.50%)

Hot Stocks
AT&T COO says company continues to see healthy demand » 19:58
12/06/22
12/06
19:58
12/06/22
19:58
T

AT&T

$19.16 /

+0.425 (+2.27%)

COO Jeff McElfresh spoke…

COO Jeff McElfresh spoke today at the UBS Global TMT Conference where he provided an update to shareholders and made the following points: 1) The company continues to see healthy customer growth in its strategic focus areas of 5G and fiber as customer demand for connectivity services remains high. While the company continues to monitor the evolving economic backdrop, McElfresh noted that AT&T continues to execute well thanks to a high-quality network and a consistent go-to-market approach and additionally feels good about its ability to attract high-quality customers. 2) In addition, McElfresh added that he feels confident in the company's strong value proposition, the resilient nature of its connectivity services and the sustainability of its wireless customer growth across multiple segments. He also said that he was pleased with the results from the company's pricing actions made in the first half of 2022. 3) McElfresh said that as the company continues to lap investments made over the past two years, it is realizing additional cost efficiencies. He shared that benefits of cost reduction measures are increasingly falling to the bottom line and driving improvements in the company's operating leverage. 4) AT&T remains committed to its guidance to achieve its target of 30 million-plus locations, including business locations, with fiber by the end of 2025. At the end of the third quarter of 2022, AT&T had the ability to serve 18.5 million consumer locations and approximately 3.0 million business customer locations in more than 100 metro areas with fiber. McElfresh said that AT&T Fiber continues to deliver the best customer experience in a competitive marketplace and he's pleased with the momentum in first-year penetration rates of about two times greater than historical norms. 5) McElfresh indicated that AT&T expects full-year capital investment in the $24 billion range to meet growing demand for core connectivity, while also meeting full-year 2022 guidance for free cash flow in the $14 billion range. The company remains focused on investing in building a sustainable and durable connectivity operation with improved cash generation and continues to be pleased with the return profile of its fiber and 5G investments.

ShowHide Related Items >><<
T AT&T
$19.16 /

+0.425 (+2.27%)

T AT&T
$19.16 /

+0.425 (+2.27%)

11/14/22 Wells Fargo
Dycom price target lowered to $120 from $130 at Wells Fargo
10/24/22 Raymond James
AT&T upgraded to Strong Buy from Outperform at Raymond James
10/24/22 Barclays
AT&T price target raised to $19 from $18 at Barclays
10/24/22 Raymond James
AT&T upgraded to Strong Buy from Outperform at Raymond James
T AT&T
$19.16 /

+0.425 (+2.27%)

T AT&T
$19.16 /

+0.425 (+2.27%)

T AT&T
$19.16 /

+0.425 (+2.27%)

T AT&T
$19.16 /

+0.425 (+2.27%)

Periodicals
Apollo, Pimco sign deal to act together in Carvana debt talks, Bloomberg says » 19:37
12/06/22
12/06
19:37
12/06/22
19:37
CVNA

Carvana

$6.70 /

-0.4 (-5.63%)

, APO

Apollo Global

$63.20 /

-1.28 (-1.99%)

, BLK

BlackRock

$710.50 /

+1.6 (+0.23%)

, ARES

Ares Management

$72.27 /

-0.2 (-0.28%)

Apollo (APO) and Pimco…

Apollo (APO) and Pimco have signed an agreement to avoid a creditor battle as they hold negotiations with Carvana (CVNA) regarding its debt, Bloomberg's Davide Scigliuzzo and Eliza Ronalds-Hannon report, citing people familiar with the matter. The group, which also includes Blackrock (BLK), Ares Management (ARES), and Knighthead Capital, intends to operate with a "united front" on negotiations around Carvana debt restructuring or new financing, the report states.

ShowHide Related Items >><<
CVNA Carvana
$6.70 /

-0.4 (-5.63%)

BLK BlackRock
$710.50 /

+1.6 (+0.23%)

ARES Ares Management
$72.27 /

-0.2 (-0.28%)

APO Apollo Global
$63.20 /

-1.28 (-1.99%)

CVNA Carvana
$6.70 /

-0.4 (-5.63%)

11/30/22 BofA
BofA downgrades Carvana to Neutral on liquidity concerns
11/30/22 BofA
Carvana downgraded to Neutral from Buy at BofA
11/22/22 Baird
Carvana downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Carvana downgraded to Market Perform from Outperform at Cowen
APO Apollo Global
$63.20 /

-1.28 (-1.99%)

11/15/22 Deutsche Bank
Apollo Global price target raised to $83 from $81 at Deutsche Bank
11/03/22 Barclays
Apollo Global price target raised to $73 from $65 at Barclays
11/03/22 Deutsche Bank
Apollo Global price target raised to $81 from $78 at Deutsche Bank
10/19/22 UBS
Apollo Global price target lowered to $55 from $60 at UBS
BLK BlackRock
$710.50 /

+1.6 (+0.23%)

11/15/22 Deutsche Bank
BlackRock price target raised to $846 from $642 at Deutsche Bank
10/18/22 Credit Suisse
BlackRock initiated with a Neutral at Credit Suisse
10/14/22 BMO Capital
BlackRock price target lowered to $481 from $495 at BMO Capital
10/14/22 JPMorgan
BlackRock price target lowered to $666 from $716 at JPMorgan
ARES Ares Management
$72.27 /

-0.2 (-0.28%)

11/15/22 UBS
Ares Management price target raised to $95 from $78 at UBS
11/14/22 BMO Capital
Ares Management downgraded to Market Perform from Outperform at BMO Capital
11/01/22 RBC Capital
Ares Management price target raised to $93 from $83 at RBC Capital
10/28/22 Barclays
Ares Management price target raised to $90 from $80 at Barclays
CVNA Carvana
$6.70 /

-0.4 (-5.63%)

BLK BlackRock
$710.50 /

+1.6 (+0.23%)

ARES Ares Management
$72.27 /

-0.2 (-0.28%)

APO Apollo Global
$63.20 /

-1.28 (-1.99%)

  • 22
    Apr
CVNA Carvana
$6.70 /

-0.4 (-5.63%)

BLK BlackRock
$710.50 /

+1.6 (+0.23%)

ARES Ares Management
$72.27 /

-0.2 (-0.28%)

APO Apollo Global
$63.20 /

-1.28 (-1.99%)

CVNA Carvana
$6.70 /

-0.4 (-5.63%)

BLK BlackRock
$710.50 /

+1.6 (+0.23%)

ARES Ares Management
$72.27 /

-0.2 (-0.28%)

APO Apollo Global
$63.20 /

-1.28 (-1.99%)

CVNA Carvana
$6.70 /

-0.4 (-5.63%)

APO Apollo Global
$63.20 /

-1.28 (-1.99%)

On The Fly
Fly Intel: After-Hours Movers » 18:38
12/06/22
12/06
18:38
12/06/22
18:38
MDB

MongoDB

$144.73 /

-4 (-2.69%)

, GWRE

Guidewire

$56.67 /

-1.08 (-1.87%)

, CASY

Casey's General Stores

$230.07 /

-0.765 (-0.33%)

, SWBI

Smith & Wesson Brands

$11.80 /

-0.275 (-2.28%)

, SKIL

Skillsoft

$1.93 /

-0.06 (-3.02%)

, ZUO

Zuora

$7.20 /

-0.18 (-2.44%)

, HQY

HealthEquity

$65.82 /

-1.915 (-2.83%)

, PLAY

Dave & Buster's

$36.14 /

-1.115 (-2.99%)

, AVAV

AeroVironment

$85.20 /

-3.92 (-4.40%)

, SFIX

Stitch Fix

$3.66 /

-0.375 (-9.29%)

, TOL

Toll Brothers

$45.82 /

-1.09 (-2.32%)

, NBIX

Neurocrine

$120.26 /

-3.4 (-2.75%)

Check out this evening's…

ShowHide Related Items >><<
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

12/05/22 Baird
MongoDB price target lowered to $205 from $330 at Baird
11/29/22 UBS
MongoDB price target lowered to $200 from $390 at UBS
11/21/22 Morgan Stanley
MongoDB downgraded at Morgan Stanley amid challenging spending environment
11/21/22 KeyBanc
MongoDB initiated with an Overweight at KeyBanc
GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

12/01/22 DA Davidson
Guidewire price target lowered to $90 from $96 at DA Davidson
12/01/22 JPMorgan
Guidewire initiated with an Overweight at JPMorgan
09/12/22 Citi
Guidewire price target lowered to $79 from $88 at Citi
09/08/22 Baird
Guidewire price target lowered to $81 from $99 at Baird
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

11/30/22 Wells Fargo
Casey's General Stores price target raised to $260 from $245 at Wells Fargo
11/29/22 Deutsche Bank
Casey's General Stores price target raised to $286 from $269 at Deutsche Bank
09/09/22 Deutsche Bank
Casey's General Stores price target lowered to $269 from $276 at Deutsche Bank
09/09/22 BMO Capital
Casey's General Stores price target raised to $250 from $235 at BMO Capital
SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

09/09/22 Lake Street
Smith & Wesson Brands price target lowered to $22 from $26 at Lake Street
SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

10/12/22 Citi
Skillsoft price target lowered to $4.50 from $13.50 at Citi
09/08/22 DA Davidson
Skillsoft price target lowered to $3 from $7 at DA Davidson
09/06/22 B. Riley
Skillsoft price target lowered to $6 from $11 at B. Riley
07/26/22 Oppenheimer
Skillsoft assumed with a Perform at Oppenheimer
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

11/28/22 Needham
Needham adds HubSpot to Conviction List, removes Zuora
10/21/22 Goldman Sachs
Zuora initiated with a Neutral at Goldman Sachs
08/25/22 Needham
Zuora price target lowered to $15 from $24 at Needham
08/25/22 Craig-Hallum
Zuora price target lowered to $16 from $22 at Craig-Hallum
HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

12/05/22 RBC Capital
HealthEquity price target raised to $75 from $70 at RBC Capital
11/02/22 Jefferies
HealthEquity price target raised to $90 from $80 at Jefferies
10/21/22 Goldman Sachs
HealthEquity upgraded to Neutral from Sell at Goldman Sachs
10/11/22 BofA
AdaptHealth, HealthEquity, ViaSat added to 'Endeavor List' at BofA
PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

11/08/22 Deutsche Bank
Dave & Buster's upgraded to Buy from Hold at Deutsche Bank
10/05/22 Piper Sandler
Dave & Buster's price target lowered to $34 from $44 at Piper Sandler
09/09/22 Deutsche Bank
Dave & Buster's price target raised to $48 from $37 at Deutsche Bank
09/08/22 Truist
Dave & Buster's price target raised to $62 from $57 at Truist
AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

11/18/22 Canaccord
AeroVironment price target raised to $105 from $100 at Canaccord
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
09/30/22 RBC Capital
AeroVironment offers best small-cap exposure to Ukraine war, says RBC Capital
SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

09/22/22 Barclays
Stitch Fix price target lowered to $5 from $7 at Barclays
09/21/22 Truist
Stitch Fix price target lowered to $6 from $8 at Truist
09/21/22 Evercore ISI
Stitch Fix price target lowered to $7 from $10 at Evercore ISI
09/21/22 MKM Partners
Stitch Fix price target lowered to $5 from $6 at MKM Partners
TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

11/22/22 JPMorgan
Toll Brothers upgraded to Overweight from Neutral at JPMorgan
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
09/19/22 KeyBanc
KeyBanc more bullish on homebuilder names, upgrades five stocks to Overweight
NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

Syndicate
X4 Pharmaceuticals announces common stock, warrant offering, no amount given » 18:27
12/06/22
12/06
18:27
12/06/22
18:27
XFOR

X4 Pharmaceuticals

$1.18 /

-0.11 (-8.53%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock. Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

11/30/22 H.C. Wainwright
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

Hot Stocks
Guaranty Bancshares director Baker buys 21,536 common shares » 18:04
12/06/22
12/06
18:04
12/06/22
18:04
GNTY

Guaranty Bancshares

$34.54 /

-0.06 (-0.17%)

In a regulatory filing,…

In a regulatory filing, Guaranty Bancshares director Richard Baker disclosed the purchase of 21,536 common shares of the company on December 5 at a price of $34.41 per share.

ShowHide Related Items >><<
GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

07/07/22 Raymond James
Guaranty Bancshares downgraded to Market Perform from Outperform at Raymond James
07/07/22 Raymond James
Guaranty Bancshares downgraded to Market Perform from Outperform at Raymond James
GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

Hot Stocks
MediciNova presents results from subgroup analysis of Phase 2 study of MN-001 » 18:03
12/06/22
12/06
18:03
12/06/22
18:03
MNOV

MediciNova

$2.40 /

-0.09 (-3.61%)

MediciNova announced that…

MediciNova announced that its Chief Medical Officer, Kazuko Matsuda, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 for the treatment of hypertriglyceridemia at the International Diabetes Federation World Diabetes Congress 2022 held online December 5 - 8. In the completed Phase 2 study, MN-001 significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease and hypertriglyceridemia. Subsequent in vitro results revealed that MN-001, or tipelukast, downregulated CD36 and upregulated ABCG1 mRNA expression, both of which are highly associated with Type 2 diabetes mellitus. Hypothesizing that MN-001 might be more effective at reducing serum triglycerides in participants with a dual diagnosis of NAFLD and Type 2 diabetes mellitus, a subgroup analysis was conducted in participants with and without T2DM. Compared to subjects without T2DM, the T2DM group showed a greater reduction in serum triglyceride levels at Week 8, 50.8% reduction for with T2DM versus 17.8% reduction for without T2DM, p&#61;0.098.

ShowHide Related Items >><<
MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

Initiation
Argenx initiated with an Outperform at William Blair » 17:56
12/06/22
12/06
17:56
12/06/22
17:56
ARGX

Argenx

$384.77 /

-8.435 (-2.15%)

William Blair analyst…

William Blair analyst Myles Minter initiated coverage of Argenx with an Outperform rating and no price target.

ShowHide Related Items >><<
ARGX Argenx
$384.77 /

-8.435 (-2.15%)

ARGX Argenx
$384.77 /

-8.435 (-2.15%)

12/06/22 Barclays
Argenx price target raised to EUR 450 from EUR 405 at Barclays
11/14/22 JPMorgan
Argenx price target raised to EUR 480 from EUR 470 at JPMorgan
10/28/22 H.C. Wainwright
Argenx price target raised to $440 from $425 at H.C. Wainwright
10/27/22 Piper Sandler
Piper Sandler remains a buyer of Argenx after Q3 beat
ARGX Argenx
$384.77 /

-8.435 (-2.15%)

  • 24
    Mar
Downgrade
Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko » 17:54
12/06/22
12/06
17:54
12/06/22
17:54
GOSS

Gossamer Bio

$2.35 /

-6.97 (-74.79%)

SMBC Nikko analyst David…

SMBC Nikko analyst David Hoang downgraded Gossamer Bio to Neutral from Outperform with a $3 price target.

ShowHide Related Items >><<
GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

12/06/22 Piper Sandler
Piper says 'Street overreacted' to Gossamer data, seralutinib still 'promising'
12/06/22 BTIG
Aerovate upgraded to Buy at BTIG after Gossamer study hits endpoint
10/20/22 Goldman Sachs
Gossamer Bio initiated with a Buy at Goldman Sachs
10/13/22 H.C. Wainwright
Gossamer Bio price target raised to $25 from $20 at H.C. Wainwright
GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

Periodicals
U.K. game sales down 7.3% y/y in November, Gamesindustry.biz says » 17:48
12/06/22
12/06
17:48
12/06/22
17:48
ATVI

Activision Blizzard

$76.12 /

-0.215 (-0.28%)

, SONY

Sony

$79.45 /

-2.205 (-2.70%)

, EA

Electronic Arts

$127.44 /

-3 (-2.30%)

, NTDOY

Nintendo

$10.43 /

+0.09 (+0.87%)

, SGAMY

Sega Sammy Holdings

$3.24 /

-0.015 (-0.46%)

More than 4.3M video game…

More than 4.3M video game units were sold in the U.K. in November, a decline of 7.3% year-over-year, Gamesindustry.biz's Christopher Dring reports, citing the latest GSD figures. While the latest "Call of Duty" games from Activision Blizzard (ATVI) typically release in November, this year's "Call of Duty: Modern Warfare II" released in October, the author notes. Meanwhile, Sony (SONY) PS5 and PS4 game "God of War Ragnarok" had a "massive launch," Dring says, with sales of the sequel up 44% in its first three weeks of release compared to 2018's "God of War." Other top sellers for the month of November in the U.K. were EA's (EA) "FIFA 23," Nintendo's (NTDOY) "Pokemon Scarlet/Violet," and Sega's (SGAMY) "Football Manager 2023." Reference Link

ShowHide Related Items >><<
SONY Sony
$79.45 /

-2.205 (-2.70%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

12/06/22 Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
11/28/22 JPMorgan
Activision Blizzard price target lowered to $86 from $95 at JPMorgan
11/28/22 Wells Fargo
Wells Fargo upgrades Activision Blizzard to Overweight with $95 price target
SONY Sony
$79.45 /

-2.205 (-2.70%)

11/02/22 Cowen
Sony price target lowered to $102 from $144 at Cowen
10/13/22 Oppenheimer
Oppenheimer sees more difficulty for Microsoft/Activision to win CMA approval
09/07/22 Goldman Sachs
Sony resumed with a Neutral at Goldman Sachs
07/08/22 Macquarie
Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie
EA Electronic Arts
$127.44 /

-3 (-2.30%)

11/28/22 Truist
Electronic Arts price target lowered to $150 from $154 at Truist
11/22/22 Truist
EA's Sports College Football timeline 'consistent' with model, says Truist
11/08/22 Deutsche Bank
Electronic Arts remains top pick in video games at Deutsche Bank
11/02/22 Wedbush
Electronic Arts price target lowered to $164 from $170 at Wedbush
NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

09/07/22 Goldman Sachs
Nintendo resumed with a Buy at Goldman Sachs
05/24/22 CLSA
Nintendo price target lowered to 51,000 yen from 53,000 yen at CLSA
03/23/22 Macquarie
Nintendo upgraded to Outperform from Neutral at Macquarie
02/16/22 Jefferies
Nintendo upgraded to Buy from Hold at Jefferies
SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

Hot Stocks
BAE Systems awarded $128.21M Army contract » 17:46
12/06/22
12/06
17:46
12/06/22
17:46
BAESY

BAE Systems

$40.45 /

+0.182 (+0.45%)

BAE Systems was awarded a…

BAE Systems was awarded a $128.21M firm-fixed-price contract for production of M88A2s. Bids were solicited via the internet with one received. Work will be performed in York, Pennsylvania, with an estimated completion date of March 31, 2025. FY10 Foreign Military Sales funds in the amount of $128.21M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

11/07/22 JPMorgan
BAE Systems price target raised to 1,100 GBp from 1,000 GBp at JPMorgan
11/07/22 Redburn
BAE Systems initiated with a Buy at Redburn
10/07/22 JPMorgan
BAE Systems price target raised to 1,000 GBp from 965 GBp at JPMorgan
08/05/22 Deutsche Bank
BAE Systems price target raised to EUR 970 from EUR 860 at Deutsche Bank
BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

Hot Stocks
Bell Textron awarded $1.36B Army contract » 17:44
12/06/22
12/06
17:44
12/06/22
17:44
TXT

Textron

$73.58 /

+3.585 (+5.12%)

Bell Textron was awarded…

Bell Textron was awarded a $1.36B hybrid contract for development of the Future Long Range Assault Aircraft weapon system. Bids were solicited via the internet with two received. Work has an estimated completion date of April 5, 2031. FY22 and FY23 research, development, test and evaluation, Army funds in the amount of $232.21M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

12/06/22 Morgan Stanley
Textron's FLRAA win should be 'positively received,' says Morgan Stanley
12/05/22 Jefferies
Textron award estimated at $11 per share net present value, says Jefferies
09/13/22 Bernstein
Textron initiated with a Market Perform at Bernstein
07/29/22 Susquehanna
Textron price target lowered to $84 from $90 at Susquehanna
TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

Hot Stocks
BRT Apartments CEO buys $285K in common stock » 17:40
12/06/22
12/06
17:40
12/06/22
17:40
BRT

BRT Apartments

$19.84 /

+0.04 (+0.20%)

In a regulatory filing,…

In a regulatory filing, BRT Apartments disclosed that its CEO Jeffrey Gould bought 14.3K shares of common stock on December 6th in a total transaction size of $285K.

ShowHide Related Items >><<
BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

11/11/22 B. Riley
BRT Apartments price target lowered to $30 from $32 at B. Riley
05/09/22 BTIG
BRT Apartments assumed with a Neutral at BTIG
03/21/22 B. Riley
BRT Apartments upgraded to Buy on strategic shift at B. Riley
03/21/22 B. Riley
BRT Apartments upgraded to Buy from Neutral at B. Riley
BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.